DexCom (DXCM) Stock Price, News & Analysis

Company Overview

DexCom, Inc. is a medical device company headquartered in San Diego, California, specializing in continuous glucose monitoring (CGM) systems for people with diabetes. The company develops, manufactures, and distributes advanced sensor-based technology designed to provide real-time glucose readings, trend data, and alerts. DexCom’s CGM platforms integrate with mobile devices, wearable insulin pumps, and digital health applications to help users and healthcare professionals make informed decisions on diabetes management.

DexCom’s flagship products include the G6 and G7 CGM systems. These systems feature small, disposable sensors that measure interstitial glucose levels every few minutes and transmit data wirelessly to a receiver or smartphone app. The G6 system was introduced in 2018 and offers factory calibration and customizable alerts, while the G7, launched in late 2022, further reduces sensor size and warm-up time. Both systems are compatible with major insulin delivery devices and support integration with telehealth platforms.

Since its founding in 1999, DexCom has grown from a small startup into a global leader in glucose monitoring technology. The company achieved its first U.S. Food and Drug Administration (FDA) approval for a CGM sensor in 2006 and expanded its regulatory clearances to Europe, Canada and parts of the Asia Pacific region over the following decade. DexCom invests heavily in research and development to advance sensor accuracy, extend wear time and enhance connectivity with digital health ecosystems.

Under the leadership of President and Chief Executive Officer Kevin Sayer, who has helmed the company since 2011, DexCom continues to pursue strategic partnerships with device manufacturers, software developers and healthcare providers. The company serves a diverse customer base that includes people with type 1 and type 2 diabetes, endocrinology clinics and integrated healthcare systems, aiming to improve glycemic control and reduce the risk of diabetes-related complications worldwide.

Key Stats

• Today's Range: $66.90 to $75.18
• 50-Day Range: $67.45 to $89.53
• 52-Week Range: $57.52 to $93.25
• Volume: 20.83 million shs
• Average Volume: 5.51 million shs
• Market Capitalization: $26.45 billion
• P/E Ratio: 46.84
• Dividend Yield: N/A
• Price Target: $99.89
• Consensus Rating: Moderate Buy

DexCom Stock Analysis - MarketRank™

DexCom scored higher than 100% of companies evaluated by MarketBeat, and ranked 12th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

DexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 14 buy ratings, 5 hold ratings, and no sell ratings.

Upside Potential

DexCom has a consensus price target of $99.89, representing about 48.1% upside from its current price of $67.45.

Amount of Analyst Coverage

DexCom has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 21.18%

Earnings Growth

Earnings for DexCom are expected to grow by 21.18% in the coming year, from $2.03 to $2.46 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DexCom is 46.84, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 280.52.

Price to Earnings Ratio vs. Sector

The P/E ratio of DexCom is 46.84, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 80.36.

Price to Earnings Growth Ratio

DexCom has a PEG Ratio of 1.41. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

DexCom has a P/B Ratio of 12.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.84% of the float of DexCom has been sold short.

Short Interest Ratio / Days to Cover

DexCom has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in DexCom has recently increased by 12.12%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DexCom does not currently pay a dividend.

Dividend Growth

DexCom does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.76

Percentage of Shares Shorted

2.84% of the float of DexCom has been sold short.

Short Interest Ratio / Days to Cover

DexCom has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in DexCom has recently increased by 12.12%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 0.89

News Sentiment

DexCom has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 34 news articles for DexCom this week, compared to 24 articles on an average week.

Search Interest

59 people have searched for DXCM on MarketBeat in the last 30 days. This is an increase of 181% compared to the previous 30 days.

MarketBeat Follows

21 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is an increase of 425% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $689,431.00 in company stock.

Percentage Held by Insiders

Only 0.32% of the stock of DexCom is held by insiders.

Percentage Held by Institutions

97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DXCM Stock Analysis - Frequently Asked Questions

How have DXCM shares performed this year?

DexCom's stock was trading at $77.77 at the beginning of the year. Since then, DXCM stock has decreased by 13.3% and is now trading at $67.45.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) announced its quarterly earnings results on Wednesday, July, 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.03. The firm's quarterly revenue was up 15.2% on a year-over-year basis.
Read the conference call transcript.

When did DexCom's stock split?

DexCom shares split on Friday, June 10th 2022.The 4-1 split was announced on Friday, March 25th 2022. The newly issued shares were distributed to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

Does DexCom have any subsidiaries?

DexCom subsidiaries include TypeZero Technologies Inc, Nintamed Handels GmbH, DexCapital LLC, DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom (Canada) Inc., DexCom Deutschland GmbH, and more.

Who are DexCom's major shareholders?

Top institutional shareholders of DexCom include Vanguard Group Inc. (12.32%), Jennison Associates LLC (2.94%), Geode Capital Management LLC (2.75%) and Sands Capital Management LLC (2.54%). Insiders that own company stock include Kevin R Sayer, Jacob Steven Leach, Jereme M Sylvain, Steven Robert Pacelli, Sadie Stern, Michael Jon Brown, Barry J Regan, Steven R Altman, Paul R Flynn, Mark G Foletta, Shelly Ramasamy Selvaraj, Matthew Vincent Dolan, Nicholas Augustinos, Bridgette P Heller and Kyle Malady.
View institutional ownership trends.

How do I buy shares of DexCom?

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DexCom investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Invesco QQQ (QQQ).

Company Calendar

• Last Earnings: 7/30/2025
• Today: 9/22/2025
• Next Earnings (Estimated): 10/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:DXCM
• CIK: 1093557
• Web: www.dexcom.com
• Phone: (858) 200-0200
• Fax: 858-200-0201
• Employees: 10,300
• Year Founded: 1999

Price Target and Rating

• Average Price Target for DexCom: $99.89
• High Price Target: $115.00
• Low Price Target: $85.00
• Potential Upside/Downside: +48.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.91
• Research Coverage: 22 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.44
• Trailing P/E Ratio: 46.84
• Forward P/E Ratio: 33.23
• P/E Growth: 1.41
• Net Income: $576.20 million
• Net Margins: 13.29%
• Pretax Margin: 18.23%
• Return on Equity: 30.41%
• Return on Assets: 10.08%

Debt

• Debt-to-Equity Ratio: 0.48
• Current Ratio: 1.52
• Quick Ratio: 1.35

Sales & Book Value

• Annual Sales: $4.03 billion
• Price / Sales: 6.56
• Cash Flow: $2.25 per share
• Price / Cash Flow: 30.01
• Book Value: $5.38 per share
• Price / Book: 12.54

Miscellaneous

• Outstanding Shares: 392,150,000
• Free Float: 390,900,000
• Market Cap: $26.45 billion
• Optionable: Optionable
• Beta: 1.48